alteration of drug accumulation in erythrocytes, thereby reducing the free drug fraction available for cellular partitioning and influencing drug distribution as well as elimination routes. The existence of CrEL and Tween  80 in blood as large polar micelles has also raised additional complexities in the case of combination chemotherapy regimens with taxanes, such that the disposition of several coadministered drugs, including anthracyclines and epipodophyllotoxins, is significantly altered. In contrast to the enhancing effects of Tween  80, addition of CrEL to the formulation of oral drug preparations seems to result in significantly diminished drug uptake and reduced circulating concentrations.
The drawbacks presented by the presence of CrEL or Tween  80 in drug formulations have instigated extensive research to develop alternative delivery forms. Currently, several strategies are in progress to develop Tween  80-and CrEL-free formulations of docetaxel and paclitaxel, which are based on pharmaceutical (e.g. albumin nanoparticles, emulsions and liposomes), chemical (e.g. polyglutamates, analogues and prodrugs), or biological (e.g. oral drug administration) strategies. These continued investigations should eventually lead to more rational and selective chemotherapeutic treatment.
Paclitaxel and docetaxel are hydrophobic antineoplastic agents demonstrating significant antitumour activity against a broad spectrum of human malignancies. After the identification of paclitaxel as the active ingredient in crude ethanolic extracts of the bark of the Pacific yew tree, Taxus brevifolia L, the development of this drug was suspended for over a decade because of problems in drug formulation. [1] After investigation of a large variety of excipients to enable parenteral administration of paclitaxel, the formulation approach using the polyoxyethylated castor oil derivative, Cremophor  EL 1 (CrEL; polyoxyethyleneglycerol triricinoleate 35) , represented the most viable option. [2] Currently, paclitaxel is commercially available as vials containing 30mg of drug dissolved in 5mL of CrEL/dehydrated ethanol USP (1 : 1 by volume). CrEL is widely used as a vehicle for the solubilisation of a number of other hydrophobic drugs, including anaesthetics, vitamins, sedatives, photosensitisers, immunosuppressives and (experimental) anticancer drugs (table I). The amount of CrEL per administration of paclitaxel is relatively high, and therefore its toxicological and therapeutic treatment with paclitaxel is of major pharmacological behaviour in the context of chemo-importance. [3] 1 Use of tradenames is for product identification only and does not imply endorsement.
The structurally related taxane docetaxel is pre-1. Physicochemical Properties of Surfactants pared by chemical manipulation of 10-deacetyl-baccatin III, an inactive precursor isolated from the needles of the European yew tree, Taxus baccata
CrEL is a white to off-white viscous liquid with L. [4] Like paclitaxel, it is a potent inhibitor of cell an approximate molecular weight of 3000Da and a specific gravity of 1.05-1.06. It is produced by the replication by stabilisation of the microtubule cytosreaction of castor oil with ethylene oxide at a molar keleton. For clinical use, this slightly less hydrophoratio of 1 : 35. Castor oil is a colourless or pale bic agent is formulated in another polyoxyethylated yellow fixed oil obtained from the seeds of Ricinus surfactant, polysorbate 80 (Tween  80). The clinicommunis, with an extremely high viscosity, and cally used formulation consists of 80mg of docetax-consists mainly of the glycerides of ricinoleic, el in 2mL of undiluted Tween  80. This non-ionic isoricinoleic, stearic, dihydroxystearic and oleic surfactant is also used to solubilise several other acids. The non-ionic surfactant produced from castanticancer drugs, including etoposide and mi-or oil is usually of highly variable composition, with nor-groove-binding cyclopropylpyrroloindole ana-the major component (about 87%) identified as oxylogues such as carzelesin (table I) .
ethylated triglycerides of ricinoleic acid (figure 1).
As a result of the heterogeneous nature of castor oil In recent years, substantial evidence has been and its variable composition, the polyoxyethylated generated suggesting that CrEL and Tween  80 are components of CrEL have been poorly characterbiologically and pharmacologically active com-ised. Using fractionation by cyclodextrin-modified pounds. In this report, we will review the physico-micellar electrokinetic capillary chromatography chemical and biological properties of both non-ionic (CD-MEKC) and UV detection, in combination surfactants, with a focus on their effects on the with delayed extraction matrix-assisted laser dedisposition characteristics of the carried drugs and sorption/ionisation time of flight mass spectrometry that of other agents administered concomitantly.
( elucidation and a semiquantitative analysis of CrEL ment activation plays a significant role. It has been components was achieved recently. [5] These inves-postulated that due to binding of naturally occurring tigations indicated that the elimination of water anticholesterol antibodies to the hydroxyl-rich surfrom ricinoleic acid during the synthesis of face of CrEL micelles, complement C3 is activated, CrEL leads to various previously unidentified leading to the clinical signs of hypersensitivity reacspecies, including (glycerol-) polyoxyethylene-tions. [16] The CrEL-induced complement activation ∆ 9,11 -didehydrostearate. It is noteworthy that equip-is clearly concentration dependent, with a minimum ment used for intravenous administration of CrEL CrEL concentration of approximately 2 µL/mL beshould be free of polyvinylchloride, since CrEL is ing required, a concentration readily achieved in capable of leaching phthalate-type plasticisers from plasma of cancer patients following standard doses polyvinylchloride infusion bags and polyethylene-of paclitaxel. [17] This explains why slowing down lined tubing sets, which can cause severe hepatic the infusion rate of paclitaxel formulated with CrEL toxicity. [6, 7] can alleviate hypersensitivity symptoms, and also In contrast to CrEL, Tween  80 is a relative explains the need for proper dissolution of CrELhomogenous and reproducible, amber-coloured, vis-containing drugs to prevent large variations in CrEL cous liquid (270-430 centistokes) with a molecular infusion rate leading to unpredictable reactions. [18] weight of 1309.7Da and a density of 1.064 g/mL. A recent investigation into the structure-activity reThe base chemical name of the major compo-lationships of surfactant-mediated complement actinent of Tween  80 is polyoxyethylene-20-sorbitan vation has shown that several analogues of CrEL monooleate (figure 1), which is structurally similar have reduced ability to induce complement activato the polyethyleneglycols. Like most non-ionic sur-tion as measured by a decrease in serum concentrafactants, CrEL and Tween  80 are capable of form-tions of the SC5b-9 marker (figure 2). Additional ing micelles in aqueous solution, with critical micel-clinical studies will be required to evaluate the clinlar concentrations of 0.009% (weight/volume) and ical utility of some of these substitute vehicles for 0.01% (weight/volume), respectively, in protein-CrEL-containing drugs. free aqueous solution. [8] In studies with dogs it was demonstrated that CrEL, mainly its minor free fatty acid constituents 2. Biological Properties of Surfactants such as oleic acid, can cause histamine release.
[20]
Despite premedication with corticosteroids and his-
Acute Hypersensitivity Reactions
tamine H1 and H2 blockers, minor reactions (e.g. flushing and rash) still occur in approximately 40% The most extensively described biological effect of all patients, [21] [22] [23] [24] with major potentially lifeof drugs formulated with CrEL is an acute hypersenthreatening reactions observed in 1.5-3% of treated sitivity reaction characterised by dyspnoea, flushpatients. [9] ing, rash, chest pain, tachycardia, hypotension, angiOleic acid is also present in Tween  80, and thus oedema and generalised urticaria, and this reaction may be a cause of hypersensitivity reactions to has been attributed to CrEL. [9] [10] [11] [12] Nevertheless, allerdocetaxel therapy or other therapies using drugs gic reactions to taxanes formulated without CrEL with Tween  80 as a solvent. Patients allergic to have been reported as well, [13] suggesting that some intravenously administered etoposide tolerated the functionality of the taxane molecule contributes, in oral formulation, which is devoid of Tween  80, part, to the observed effect. Already in the 1970s it very well. [25] [26] [27] [28] The early clinical studies with was demonstrated that CrEL-containing drug prepadocetaxel revealed an incidence of hypersensitivity rations (e.g. rectal diazepam) can cause complement reactions ranging from 5-40%, with only a minority activation. [14, 15] The mechanistic basis for this effect of more than grade 2 on the 4-point scale of the has not been fully elucidated, but a number of seminal studies indicate that CrEL-mediated comple-National Cancer Institute common toxicity crite- Experiments were based on 50µL human serum incubations (45 minutes at 37°C) in the presence of each respective vehicle at a concentration of 10 µL/mL. The complement activation marker SC5b-9 was measured by enzyme-linked immunoassay. Data are presented as mean values ± SD of triplicate observations and were obtained from Loos et al. [19] ria. [29] [30] [31] Hypersensitivity reactions to docetaxel demyelinisation in rat dorsal root ganglion neutherapy can be effectively ameliorated by premedi-rons. [39, 40] The precise mechanism of this CrELcation with corticosteroids and antihistamines, [32] induced neurotoxicity remains unclear, but recent consistent with a role of histamine in its aetiology. A work has indicated that unsaturated fatty acids may comparative evaluation of paclitaxel-and docetaxel-cause neurotoxicity, possibly due to the appearance mediated non-haematological toxicities, with the of peroxidation products. [39, 40] This suggests that the drugs given in an every 21-day schedule, is provided ethoxylated derivatives of castor oil probably acin table II. count for most of the neuronal damage in addition to the presence of residual ethylene oxide residues.
[41]
Peripheral Neurotoxicity
A detailed investigation into neurological ad-A well-known adverse effect of agents formulat-verse effects associated with docetaxel chemothered in CrEL is peripheral neurotoxicity, [35] but it is apy was recently performed in a group of 186 paless well acknowledged that CrEL may play an tients.
[42] Twenty-one patients developed mild to important causative role. In a study performed with moderate sensory neuropathy on treatment at a wide radiolabelled paclitaxel in rats, no detectable pacli-range of cumulative doses (50-750 mg/m 2 ) and dose taxel could be demonstrated in the peripheral nerve levels (10-115 mg/m 2 ). Ten of these patients also fibres, [36] but electrophysiological studies in patients developed weakness in proximal and distal extremiwith neuropathy after treatment with paclitaxel have ties of varying degree. Nine of the 21 patients had shown evidence of both axonal degeneration and received neurotoxic chemotherapy before, and 16 demyelinisation. [37] In approximately 25% of pawere treated with docetaxel at a dose level of tients treated with cyclosporin, neurotoxicity is not-100-115 mg/m 2 . This suggests that docetaxel proed. [38] This adverse effect is never induced by oral duces a mild and predominantly sensory neuropathy formulations of cyclosporin, which is consistent in a high proportion of treated patients. This adverse with observations that CrEL is not absorbed intact effect appears to be dose-dependent and may be when given orally. Moreover, CrEL plasma concensevere and disabling at higher dose levels. [42] [43] [44] Cortrations achieved with therapeutic doses of intraveticosteroid comedication does not prevent docetaxnous paclitaxel or cyclosporin have been shown to el-induced neuropathy. [45] produce axonal swelling, vesicular degeneration and paclitaxel and docetaxel, with formulation vehicles contributing to the overall picture to a different extent.
Dyslipidaemia
In the mid-1970s, lipoprotein alterations caused by CrEL were mentioned for the first time. [48] Later, CrEL was found to alter the buoyant density of highdensity lipoprotein (HDL) and shift the electrophoretic and density gradient HDL to low-density lipoprotein (LDL). [49] [50] [51] [52] These authors demonstrated the strong affinity of paclitaxel for serum lipoprotein degradation products, potentially affecting the pharmacokinetics of the drug by altering protein binding characteristics. High concentrations of CrEL may also cause dyslipidaemia, possibly resulting in rouleaux formation of erythrocytes.
[53] Although cyclosporin is known for its atherosclerosisinducing capacities, it remains unclear if the observed hyperlipidaemia after CrEL administration is contributing to this risk for vascular accidents. In vivo studies of the effects of cyclosporin on the deendothelialised carotid artery of New Zealand White rabbits treated with therapeutic doses of cyclosporin (15 mg/kg/day) or with a vehicle control (CrEL) revealed intimal proliferation in both groups. [54] Mean plasma cholesterol levels were moderately increased in both groups. Although this may have contributed to foam cell formation in the cyclosporin-treated animals, it was not the sole determinant, as foam-cell-rich lesions were not observed in animals receiving only CrEL. In contrast, Tatou et al. observed significant adverse effects of CrEL on Severe (at least grade 3) 0 2.5
Peripheral neuropathy e All 60 49
Severe (at least grade 3) 3 4
Skin toxicity f All 2 48
Severe (at least grade 3) 0 5
a Data represent overall incidence as percentage of patients with solid tumours treated with single-agent regimens containing either paclitaxel formulated in a mixture of Cremophor  EL and ethanol at doses of 135-300 mg/m 2 or docetaxel formulated in Tween  80 at a dose of 100 mg/m 2 , given every 21 days. [33, 34] b All patients received a 3-day dexamethasone premedication (docetaxel, n = 92).
c Characterised by one or more of the following events: poorly tolerated peripheral oedema, generalised oedema, pleural effusion requiring urgent drainage, dyspnoea at rest, cardiac tamponade, or pronounced abdominal distension (due to ascites).
d Mostly changes in pigmentation or discoloration of the nail bed.
e Mostly peripheral sensory (numbness, paraesthesias, loss of proprioception), axonal degeneration and secondary demyelination.
f Primarily involves pressure or trauma sites (e.g. hands, feet and elbows).
endothelial function and vascular muscle on isolated and perfused rat hearts, leading to a reduction of Tween  80 is capable of producing vesicular coronary flow and aortic output. [55] The potential degeneration. This property depends upon the poly-clinical implications with respect to these CrELrelated phenomena remain unknown. ethylene substitutions produced by reaction of the polyol compound with ethylene oxide. However, the 2.4 Inhibition of P-Glycoprotein Activity incidence of neurotoxicity during treatment with docetaxel is much lower as compared to that of P-glycoprotein is a drug transporting membrane paclitaxel (table II) . [46, 47] Furthermore, the Tween  protein, and its expression is increased in tumour 80-containing epipodophyllotoxin etoposide is not cells having a multidrug resistance phenotype. [56, 57] known to be neurotoxic. This suggests that the aeti-Several in vitro studies in the early 1990s observed ology of taxane-induced neuropathy is different for modulation of the activity of P-glycoprotein by CrEL. [58] [59] [60] Later, similar phenomena were observed 3. Pharmacological Properties of Surfactants for various other non-ionic surfactants, including Tween  80, [61, 62] Solutol HS 15 [63] and Triton X-100. [64] However, in vivo studies never demon-3.1 Analytical Methods strated reversal of multidrug resistance by any nonAt present, a large variety of analytical proceionic surfactant, including CrEL and Tween  dures are available for clinical pharmacokinetic 80.
[ [65] [66] [67] The extremely low volume of distribution studies with CrEL and Tween  80. The first assay of CrEL and the rapid degradation of Tween  80 in developed for measurement of CrEL concentrations vivo are the likely explanations for this lack of in in patient material was based on the ability of vivo efficacy (see section 3.2). Indeed, the volume of this vehicle to modulate daunorubicin efflux in distribution of CrEL is approximately equal to the multidrug resistant T-cell leukaemia VLB 100 volume of the blood compartment, suggesting that cells. [83] Alternatively, a more sensitive and reliable concentrations necessary to affect reversal of mulmethod was developed that required sample tidrug resistance in vitro are not reached in vivo in volumes of only 20µL. [84] This method is based on solid tumours. [68] However, it should be noted that measurement of ricinoleic acid after base-inthe pharmacokinetic selectivity of CrEL for the cenduced hydrolysis (saponification) of CrEL foltral blood and bone marrow compartment can prolowed by an acylchloride formation, precolumn vide an advantage to treatment of haematological derivatisation with naphthylamine, and reversedmalignancies with resistance to chemotherapy phase high-performance liquid chromatography caused by elevated P-glycoprotein expression. [69] (HPLC) to detect N-ricinoleoyl-1-naphthylamine at 280nm. Because of the high costs and the time-
Intrinsic Antitumour Effects
consuming nature of both assays, a new method, based on a selective binding of CrEL to the CoomasCell-growth inhibitory properties of CrEL were sie Brilliant Blue G-250 dye in protein-free extracts first observed by Fjällskog et al. in doxorubicin-was developed for human plasma samples. [85, 86] This resistant human breast cancer cell lines, [70, 71] and method has also been used to measure Tween  80 were later confirmed in other malignant cell concentrations in murine and human plasma. [87] types. [72, 73] The formation of free radicals by perox-More recently, a potentiometric titration method for idation of polyunsaturated fatty acids and/or a direct CrEL was developed for quantitative analysis in perturbing effect on the cell membrane are possible urine and plasma based on coated wire electrode as mechanisms responsible for this type of cell growth an end-point indicator with sodium teinhibition. [74] [75] [76] Using in vitro clonogenic assays, traphenylborate at 20 o C and pH 10. [88] Each of these however, it has been demonstrated that CrEL, at methods has its drawbacks and limitations, and the clinically achievable concentrations, can antagonise methodological differences between them probably the cytotoxicity of paclitaxel by a cell-cycle contribute to the variations in measured CrEL conblock. [77] Several reports also suggest that Tween  centrations. 80 has intrinsic antitumour activity in animal modIn addition to the Coomassie Brilliant Blue Gels, [78] [79] [80] which might be linked to the release of 250 colourimetric dye-binding assay, various other oleic acid, a fatty acid known to interfere with analytical procedures are available for Tween  80. malignant cell proliferation due to formation of per-Initially measurement of the polyoxyethylated poroxides [81] and inhibition of angiogenesis. [82] The ex-tion of the molecule was used for quantification of act contribution of Tween  80 to antitumour ac-Tween  80 concentrations. The so-called polyol tivity observed in patients treated with chemothera-moiety is detectable by a wide variety of methods, peutic drugs formulated in this vehicle substance has including a resorcinol-glucose precipitation, a not been clarified.
colourimetric method using ammonium cobaltoth-1-3 and 24 hours, CrEL clearance increased from about 160 to 300 and 400 mL/h/m 2 , respectively (figure 3). [17] A recently developed population pharmacokinetic model revealed that the plasma concentration-time data of CrEL were best fitted to a threecompartment model with Michaelis-Menten elimination (table III) . [98, 99] It thus appears that CrEL shows schedule-dependent pharmacokinetics, possibly related to saturated elimination due to capacity-limited CrEL metabolism within the systemic circulation. This schedule dependency leads to an increase in systemic exposure, and thus an increase in CrEL-related biological effects, with shortening of the infusion duration. An example of this phenomenon is the apparent increase of allergic reactions in 1-hour versus 3-or 24-hour infusions of paclitaxel, [9, 100] as well as in- [17]
creased incidence of peripheral neuropathy with shorter paclitaxel infusions. [101, 102] The observed iocyanate, turbidimetric or gravimetric procechanges in adverse effects as a function of paclitaxel dures, and complex formation with barium phosphoinfusion duration will need to be confirmed in larger molybdic reagent.
[89,90] The ammonium cobaltothiocyanate complexation has also been used in comparative trials in order to provide recommendacombination with HPLC and UV detection for ana-tions for treating clinicians. lysis of Tween  80 in urine and ascites fluid, using either post-column or on-line complexation.
[91-94] A less complex procedure that does not require complexation involves a one-step hydrolysis with sulphuric acid followed by HPLC with UV detection at 210nm. [95] Most recently, Tween  80 concentration in human plasma samples have been analysed by a liquid chromatographic assay with tandem massspectrometric detection, with a 60-fold increased sensitivity as compared with previous published assays.
[96]
Pharmacokinetics
The various analytical methods described above have been used in different pharmacokinetic studies of CrEL, sometimes leading to conflicting results and conclusions. There have been no studies thus far comparing the different analytical methods. Initial pharmacokinetic analyses have indicated that CrEL shows linear pharmacokinetic behaviour. [97] However, with prolongation of infusion duration from Km = plasma concentration at half Vmax; Q2, Q3 = intercompartmental clearances from the central to the first or second peripheral compartments; RSE = relative standard error; Vmax = maximum elimination rate; V1, V2, V3 = volumes of the central, first peripheral and second peripheral compartments.
The terminal half-life of CrEL amounts to approximately 80 hours with reported values ranging between 10 and 140 hours, depending on the sampling time period and the method used for CrEL analysis. Therefore, studies using sparse-sampling strategies with application of the bioassay method may lead to underestimation of the terminal halflife. [103] With the more sensitive colourimetric assay, detectable concentrations of CrEL were demonstrated even 1 week after initial treatment. [68] Despite this relatively long terminal disposition phase of CrEL, long-term weekly administration of paclitaxel does not cause significant accumulation of CrEL although the vehicle is always detectable in pre-dose samples. [104] In all studies, the observed volume of distribution of CrEL was extremely small and almost equal to the volume of the central blood centrations of Tween  80 of 0.16 ± 0.05 µL/mL, compartment. As outlined, this implies that tissue consistent with more recent observations. [96, 107] In and tumour delivery of CrEL is insignificant. [68] vitro experiments have shown that this rapid elimiLittle is known about elimination routes of CrEL. nation is caused by a rapid carboxylesterase-mediPharmacokinetic studies in patients with hepatic ated hydrolysis in the systemic circulation, cleaving dysfunction treated with paclitaxel suggested that the oleic acid side chain from the molecule.
[87] Earlihepatobiliary elimination of CrEL is not of major er studies performed in rats and humans with the importance. [105] Despite its highly hydrophilic na-structurally related surfactants polysorbate 20 and ture, the renal elimination of CrEL accounts for less polysorbate 40 have shown similar metabolic paththan 0.1% of the administered dose and CrEL ways, with ester bond cleavage and subsequent oxipharmacokinetics in a patient with severely im-dation of the fatty acid moiety (reviewed in Van paired renal function were not different from those Zuylen et al. [108] ). in historical controls. [106] It is possible that elimination pathways for CrEL are mainly dictated by se-
Modulation of Drug rum carboxylesterase-induced degradation, leading
Disposition Patterns to the release of free fatty acids such as ricinoleic acid. This metabolic route occurs apparently at a low
Intravenous Administration
rate and the involved enzymes may be easily saturated, which explains the peculiar time-dependent nonVarious studies have shown that CrEL alters the linear pharmacokinetics of this vehicle.
pharmacokinetic behaviour of many drugs adminisThe pharmacokinetic behaviour of Tween  80 is tered intravenously, including cyclosporin, anthravery different from that of CrEL. In animal studies a cyclines, etoposide, the irinotecan metabolite SN38, rapid decline of the concentration was shown after the photosensitiser C8KC and paclitaxel (table IV) . injection (figure 4). Plasma concentrations were be-The most common effect is a substantial increase in low 0.05 µL/mL (i.e. the lower limit of quantifica-the systemic exposure to the studied agent with a tion of the analytical method) within 15 minutes concomitantly reduced systemic clearance, as was after drug administration. [87] Observations in five first described for paclitaxel in a mouse model (figpatients treated with docetaxel as a 1-hour infusion ure 5). Various proposed causes of the CrEL-drug at a dose of 100 mg/m 2 showed peak plasma con-interactions have been put forward in recent years, Vigabatrin Rat Increased GABA in brain 128 AUC = area under the plasma concentration-time curve; Cmax = peak plasma concentration; GABA = γ-aminobutyric acid; t1/2β = half-life of the terminal disposition phase.
including altered protein binding characteristics, [52] drug from reaching the sites of metabolism and excretion, [109] and the same effect was noted for altered hepatobiliary secretion, [109] and inhibition of Tween  80. [111] However, recent studies indicate endogenous P-glycoprotein-mediated biliary secrethat drug-transporting P-glycoproteins are not estion, thereby reducing elimination of drugs. [110] In sential for normal hepatobiliary secretion of paclithe isolated perfused rat liver, CrEL inhibited the taxel, [112] suggesting that this protein does not play a hepatic elimination of paclitaxel, preventing the major role. [8] In view of the very small volume of distribution of CrEL, it is likely that the pharmacokinetic interaction observed with some drugs takes place within the central blood compartment. This was recently confirmed by in vitro experiments demonstrating that encapsulation of the model drug paclitaxel within the hydrophobic interior of CrEL micelles takes place in a concentration-dependent manner, causing changes in cellular partitioning and blood:plasma concentration ratios of paclitaxel (table V) . [8, 19] It was shown that the affinity of paclitaxel was (in decreasing order) CrEL > plasma > human serum albumin, with CrEL present above the critical micellar concentration (i.e. ~0.01%). Since the effect was also observed in the absence of plasma proteins, it could not have been caused by altered protein binding or by an increased affinity of paclitaxel for protein dissociation products that are produced by the action of CrEL on native lipoproteins. [51, 52] These findings are consistent with the hypothesis that paclitaxel can be entrapped within micelles, and that these micelles act as the principal carrier of paclitaxel in the systemic circulation.
An intriguing feature of paclitaxel pharmacokinetics is a distinct dose-dependent pharmacokinetic behaviour, with clearance values decreasing substantially with an increase in drug dose. This effect is particularly evident with 3-hour infusion regimens, and CrEL has been linked to this phenomenon. It has been shown that the percentage of total paclitaxel trapped in micelles increases disproportionally with higher doses of CrEL administered, [8] thereby influencing the unbound drug concentration and making it less available for distribution to tissues, metabolism, and biliary and intestinal secretion. Indeed, the free fraction of paclitaxel is inversely related to CrEL concentrations in vitro, [129] and CrEL has also been shown to alter the blood : plasma concentration ratios in vivo by reducing drug uptake into red blood cells.
[130] Interestingly, when paclitaxel dissolved in another vehicle was administered to mice, no pharmacokinetic non- CrEL fraction 5 (5) 0.943 ± 0.039 -11.9 0.103 a Paclitaxel was used at an initial concentration of 1 µg/mL and incubated in whole blood for 15 min at 37°C before fractionation and analysis by high-performance liquid chromatography. Ratio data are presented as mean values ± SD of (at least) triplicate measurements and were obtained from Sparreboom et al. [8] b Probability of significant difference versus control (unpaired two-sided Student's t test).
c Five CrEL fractions, each with progressively increased hydrophobicity, were isolated as chromatographic peaks, as described elsewhere. [8] The fractionation process was based on reversed-phase high-performance liquid chromatography of crude CrEL. The first fractions mainly contain polyoxyethyleneglycerol and oxyethylated glycerol, and the pharmacologically active fraction 4 contains the micelle-forming component, polyoxyethyleneglycerol triricinoleate along with fatty acid esters of polyethyleneglycerol. linearity in plasma concentration profiles was evident.
[122] The concentrations in tissues also in-paclitaxel, distribution to red blood cells and bindcreased linearly with increasing dose even when ing to serum albumin, α1-acid glycoprotein and dissolved in CrEL, suggesting linear kinetics for the platelets. The results of that study showed that the unbound drug.
nonlinear pharmacokinetics are predominantly explained by nonlinear binding to CrEL and that the Earlier, the nonlinearity in paclitaxel pharmacounbound drug displayed linear pharmacokinetics kinetics had been described by empirical models when administered over a 3-hour period. using both saturable elimination and saturable distribution, where the saturable distribution has been
The drug fraction not bound to serum proteins or described as saturable transport [131] or saturable CrEL is a rather small fraction of the total under binding. [132] A recent study demonstrated that a normal physiological conditions, and at high conmechanistic model could be used to describe the centrations, paclitaxel is mainly bound to CrEL. nonlinear kinetics of the drug using simultaneous From simulated concentration components in padescription of total and unbound plasma concentra-tients treated with 24-hour infusions, it was demontions, whole blood concentrations and concomitant strated that because CrEL concentrations are rather CrEL concentrations. [133] This pharmacokinetic low, the linear binding to serum proteins and bindmodel has a foundation in the known properties of ing to blood cells are of greater importance than the paclitaxel as determined with micellar trapping of CrEL binding. [133] Because of the schedule-depen-dent clearance of CrEL, this has serious clinical ramifications in that the systemic exposure to unbound paclitaxel will be a function of infusion duration. This was recently confirmed in a randomised comparative clinical trial evaluating drug disposition characteristics following 1-versus 3-hour infusions. [102] The area under the plasma concentrationtime curve (AUC) of unbound paclitaxel was 24% (p = 0.009) reduced as compared with the 3-hour infusion group (figure 6), despite significantly higher peak concentrations (0.26 ± 0.007 vs 0.15 ± 0.07 µmol/L; p = 0.0002). Most importantly, this effect translated into more severe haematological toxicity with the 3-hour schedule of drug administration, [102] suggesting that the various infusion schedules currently employed for paclitaxel administration are not interchangeable or pharmacologically equivalent. The existence of CrEL in blood as large polar micelles with a highly hydrophobic interior also of incorporation of the anthracycline drug into CrEL raises the possibility of interactions occurring with micelles. [134] In this respect, several studies have other (poorly water-soluble) drugs. For example, the demonstrated significant pharmacokinetic interaccombination of paclitaxel with anthracycline drugs tions between paclitaxel and/or CrEL and doxomay result in altered cellular distribution and a conrubicin. [110, 114, 117, 135 ,136] Although not tested explicitcomitantly increased plasma concentration, because ly, it is likely that the presence of CrEL in the clinical formulation of certain drugs contributes, at least in part, to various pharmacokinetic interactions described with other agents (table VI) .
There are conflicting reports in the literature on the effects of Tween  80 on the distribution and elimination of drugs administered intravenously (table IV) . In mice it was demonstrated that Tween  80 caused an increase of doxorubicin plasma concentrations by decreasing the plasma volume as a result of the osmotic effect of Tween  80 on total blood volume. [124, 125] However, in patients receiving the same relative amount of Tween  80 (administered concomitantly with etoposide at a dose of 100 mg/m 2 ), both the volume of distribution and the clearance of doxorubicin were increased, due to reduced plasma concentrations of doxorubicin in the early phase of the concentration-time profile. [126] In the isolated perfused rat liver, Tween  80 decreased the clearance and the volume of distribution of eto- receiving a 1-hour (n = 15; mean ± SD AUC 0.50 ± 0.10 µmol • h/L) or a 3-hour infusion (n = 14; mean ± SD AUC 0.62 ± 0.12 µmol • h/ L) and were obtained from Gelderblom et al. [102] Each symbol represents the AUC of an individual patient, and the horizontal lines indicate mean values for each group. AUC = area under the concentration-time curve.
poside, [111] but it increased the renal and biliary non might be the result of Tween  80 metabolism excretion of methotrexate. [127] The majority of clin-by serum esterases and subsequent oleic acid-mediical investigations have shown minimal alteration in ated protein-binding displacement of docetaxel, the pharmacokinetic profiles of agents when used in causing increases in unbound drug. [152] Regardless combination with drugs formulated in Tween  of the mechanism underlying this effect, it is consis-80. [135, 147, 148] This is most likely the result of the tent with recent observations that, similar to paclirapid degradation of Tween  80 in plasma by ester-taxel, also in the case of docetaxel nonlinear distriases, such that it cannot interfere to any significant bution pathways exist that may be related to the extent with the pharmacokinetic behaviour of other presence of non-ionic surfactants in the clinical foragents. mulated product. [153] However, recent observations indicate that
Extravascular Routes of Administration
Tween  80, at concentrations observed in patients treated with docetaxel, causes a profound and signifThere have been many reports highlighting the icant alteration of the fraction unbound of docetaxel, ability of Tween  80 to increase the absorption in in which increased by 50% (figure 7). [149] The mechan-vitro systems, animals and humans of numerous istic basis for the decreased binding of docetaxel in agents involving various classes of drug. Typical the presence of Tween  80, contrary to that observ-examples of this phenomenon are provided in table ed with CrEL and paclitaxel, is as yet unclear. It is VII. The main overall conclusion from these studies possible, however, that with time Tween  80 is able is that Tween  80 acts as an enhancer of the systemto form micellar complexes with proteins, including ic exposure to orally administered agents by increasserum albumin and α1-acid glycoprotein, so that the ing biomembrane permeability, [154, 155] as has also binding of docetaxel becomes saturable on single been described for intravesical instillation of thisites. [150] Similar observations have been reported otepa in the presence of Tween  80 in cancer pafor the binding of several other drugs that bind with tients. [156] It has also been proposed that agents like high affinity but low capacity to α1-acid glycoprote-Tween  80 and CrEL not only support solubilisain in the presence of structurally-related mixed-tion, but also may inhibit the activity of P-glycopromicellar systems. [151] Alternatively, the phenome-tein with oral administration. [157, 158] This protein is a membrane-bound drug efflux pump, which is abundantly present in the gastrointestinal tract, [159, 160] and mediates direct secretion of substrate drugs into the intestinal lumen, thereby limiting its oral uptake. [112] However, following oral administration, polyoxyethylated surfactants are known to be extensively metabolised in the intestine by pancreatic lipases into the free fatty acid and the polyol moiety, with only less than 3% of the administered dose being excreted into the urine. [108] This makes it unlikely that the modulating effects are predominantly caused by a direct influence on active drug transport by the intact vehicles.
In contrast to the enhancing effects of Tween  80, addition of CrEL to the formulation of oral drug preparations, in general, seems to result in significantly diminished drug uptake and reduced circulating concentrations (table VII) . One of the best stud- [149] a As compared with a Tween  80 formulation.
b As compared with a formulation containing 7-fold less Cremophor  EL.
c As compared with a nanosphere formulation. AUC = area under the plasma concentration-time curve; PIVKA-II = des-gamma-carboxyprothrombin.
ied examples is the influence of CrEL on the oral 80, [179] suggesting that the effect is CrEL specific, and that other formulations should be developed in absorption of paclitaxel. Oral administration of this order to increase the usefulness of oral paclitaxel drug is an attractive alternative for the currently administration. used intravenous regimen, because it is convenient and practical for patients and it may circumvent Entrapment of drug in CrEL micelles has also systemic exposure to CrEL, which is known to be been demonstrated for several agents delivered innot absorbed intact after oral administration. [173, 174] traperitoneally (e.g. O 6 -benzylguanine in mice [180] A study of paclitaxel formulated in Tween  80 resulted in a significant increase in the peak concentration and AUC of paclitaxel in comparison with the CrEL formulations. [162, 163] Fecal elimination data revealed a decrease in excretion of unchanged paclitaxel for the Tween  80 formulation compared with the CrEL formulations, suggesting that entrapment of paclitaxel in CrEL micelles is an important factor limiting the absorption of orally administered paclitaxel from the intestinal lumen. Obviously, this has significant clinical ramifications in that oral paclitaxel shows very distinct apparent saturable absorption kinetics with no further increase of the AUC with a given increase in dose (figure 8). [175] [176] [177] [178] Similar dose-dependence was not observed with oral administration of docetaxel formulated in Tween  ovarian carcinoma, since paclitaxel has proven single-agent activity in this disease. [184] With this route of drug administration, the presence of CrEL as an integral component of the clinical formulation may actually be advantageous as it prolongs exposure to the tumour cells and reduces transport across the peritoneal/blood barrier (table VIII).
Conclusion
Numerous investigations have studied the role of pharmaceutical vehicles such as CrEL and Tween  [123] b Probability of significant difference versus control (two-sided test for matched pairs). AUC = area under the plasma concentration-time curve; Cmax = peak plasma concentration; F = bioavailability.
80 in the pharmacological behaviour of the formulated drugs. These investigations have yielded funand paclitaxel in cancer patients [123] ) or intravesical-damental insight into modes of action, pharmacoly (e.g. paclitaxel in dogs [181] ). The major goal of kinetic profiles and considerations of dosage and intraperitoneal therapeutic strategies is to expose scheduling. Indeed, the administration of CrEL and tumours within the peritoneal cavity to higher con-Tween  80 to patients presents a number of serious centrations of antineoplastic agents for longer peri-concerns, including unpredictable intrinsic adverse ods of time than can be achieved by systemic drug effects such as acute hypersensitivity reaction and administration. [182, 183] Treatment with paclitaxel giv-peripheral neuropathy. Furthermore, these suben intraperitoneally is attractive in patients with stances modulate the disposition profiles of various Tween  80 and CrEL, respectively. [185] A recent dose-finding study with a new submicronic Tween  
